NovaBridge Biosciences
NBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001778016
In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 3 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding NovaBridge Biosciences changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 39 | 38 | −1 |
| Shares | 12.2M | 15.1M | +2.95M (+24.2%) |
| Value | $22.7M | $25.3M | +$2.65M (+11.7%) |
New holders (3)
Institutions that held NovaBridge Biosciences at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of Montreal | 244,875 | $453.0K | 0.00% |
| Citadel Advisors LLC | 38,708 | $64.6K | 0.00% |
| Susquehanna International Group, LLP | 31,066 | $51.9K | 0.00% |
Sold out (4)
Institutions that held NovaBridge Biosciences at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Man Group plc | 134,977 | $251.1K |
| Prelude Capital Management, LLC | 81,262 | $151.1K |
| Atom Investors LP | 29,612 | $55.1K |
| Simplex Trading, LLC | 84 | $0 |